Table 3.
Final causal relationship between inflammatory bowel disease, Crohn’s disease, ulcerative colitis and 32 site-specific extracolonic cancer
| Phenotypes | Inflammatory bowel disease | Crohn’s disease | Ulcerative colitis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Data sources | OR (95% CI) | P | Data sources | OR (95% CI) | P | Data sources | OR (95% CI) | P | |
| Respiratory system | |||||||||
| Larynx | UKB + FinnGen | 0.904 (0.813, 1.005) | 0.062 | UKB + FinnGen | 0.915 (0.833, 1.006) | 0.067 | UKB + FinnGen | 0.960 (0.859, 1.072) | 0.469 |
| Bronchus and lung | UKB + FinnGen + ILCCO | 1.008 (0.984, 1.033) | 0.504 | UKB + ILCCO | 1.008 (0.965, 1.053) | 0.729 | UKB + FinnGen + ILCCO | 1.014 (0.989, 1.040) | 0.273 |
| Oral cavity and pharynx | |||||||||
| Oral cavity | Lesseur, C | 1.180 (1.059, 1.316) | 0.003 | Lesseur, C | 1.112 (1.008, 1.227) | 0.034 | Lesseur, C | 1.158 (1.041, 1.288) | 0.007 |
| Pharynx | Lesseur, C | 1.011 (0.909, 1.125) | 0.836 | Lesseur, C | 1.019 (0.927, 1.121) | 0.696 | Lesseur, C | 1.035 (0.924, 1.159) | 0.553 |
| Digestive system cancer | |||||||||
| Esophagus | UKB + FinnGen | 0.948 (0.889, 1.011) | 0.103 | UKB + FinnGen | 0.969 (0.917, 1.024) | 0.263 | UKB + FinnGen | 0.966 (0.899, 1.037) | 0.335 |
| Small intestine | UKB + FinnGen | 0.971 (0.881, 1.071) | 0.556 | UKB + FinnGen | 1.003 (0.921, 1.092) | 0.953 | UKB + FinnGen | 1.009 (0.829, 1.227) | 0.932 |
| Stomach | UKB + FinnGen | 1.005 (0.925, 1.092) | 0.912 | UKB + FinnGen | 1.008 (0.960, 1.059) | 0.736 | UKB + FinnGen | 0.993 (0.932, 1.057) | 0.820 |
| Pancreas | UKB + FinnGen + PanScan | 1.007 (0.956, 1.060) | 0.797 | UKB + FinnGen + PanScan | 0.992 (0.950, 1.036) | 0.714 | UKB + FinnGen + PanScan | 1.029 (0.971, 1.089) | 0.338 |
| Hepatocellular | UKB | 0.923 (0.743, 1.148) | 0.473 | UKB | 0.949 (0.785, 1.147) | 0.586 | UKB | 0.908 (0.714, 1.156) | 0.432 |
| Hepatic bile duct | UKB | 1.082 (0.849, 1.379) | 0.546 | UKB | 1.170 (0.948, 1.444) | 0.144 | UKB | 1.020 (0.792, 1.313) | 0.879 |
| Extrahepatic bile duct | UKB | 0.919 (0.775, 1.090) | 0.332 | UKB | 0.964 (0.831, 1.118) | 0.626 | UKB | 0.928 (0.772, 1.116) | 0.428 |
| Hematologic malignancy | |||||||||
| Multiple myeloma | UKB + FinnGen | 1.012 (0.886, 1.155) | 0.863 | UKB + FinnGen | 1.030 (0.919, 1.155) | 0.611 | UKB + FinnGen | 1.029 (0.963, 1.100) | 0.398 |
| Hodgkin lymphoma | UKB + FinnGen | 1.005 (0.927, 1.090) | 0.897 | UKB + FinnGen | 1.013 (0.943, 1.088) | 0.729 | UKB + FinnGen | 1.004 (0.916, 1.101) | 0.932 |
| Non-Hodgkin lymphoma | UKB | 1.007 (0.954, 1.064) | 0.796 | UKB | 0.997 (0.950, 1.047) | 0.914 | UKB | 1.027 (0.967, 1.092) | 0.385 |
| Acute myelocytic leukemia | UKB + FinnGen | 0.978 (0.821, 1.164) | 0.799 | UKB + FinnGen | 1.035 (0.819, 1.308) | 0.775 | UKB + FinnGen | 1.014 (0.903, 1.139) | 0.814 |
| Chronic myeloid leukemia | UKB + FinnGen | 0.926 (0.733, 1.169) | 0.517 | UKB + FinnGen | 0.907 (0.795, 1.036) | 0.150 | UKB + FinnGen | 0.902 (0.760, 1.071) | 0.240 |
| Chronic lymphocytic leukemia | UKB + FinnGen | 1.022 (0.945, 1.106) | 0.581 | UKB + FinnGen | 0.988 (0.924, 1.057) | 0.734 | UKB + FinnGen | 1.022 (0.905, 1.153) | 0.728 |
| Genital system | |||||||||
| Ovary | UKB + FinnGen + OCAC | 0.993 (0.971, 1.015) | 0.535 | UKB + FinnGen + OCAC | 1.004 (0.986, 1.023) | 0.646 | UKB + FinnGen + OCAC | 0.983 (0.961, 1.006) | 0.148 |
| Uterine cervix | UKB + FinnGen | 1.027 (0.980, 1.075) | 0.265 | UKB + FinnGen | 1.031 (0.991, 1.072) | 0.132 | UKB + FinnGen | 1.017 (0.987, 1.048) | 0.258 |
| Uterine corpus | UKB + FinnGen + O’Mara et.al | 0.982 (0.959, 1.006) | 0.140 | FinnGen + O’Mara et.al | 0.994 (0.972, 1.017) | 0.598 | UKB + FinnGen + O’Mara et.al | 0.986 (0.961, 1.012) | 0.292 |
| Vulva | UKB + FinnGen | 0.995 (0.871, 1.136) | 0.940 | UKB + FinnGen | 1.011 (0.806, 1.267) | 0.926 | UKB + FinnGen | 0.904 (0.779, 1.050) | 0.187 |
| Testis | UKB + FinnGen | 0.976 (0.892, 1.068) | 0.600 | UKB + FinnGen | 1.014 (0.938, 1.097) | 0.727 | UKB + FinnGen | 0.996 (0.902, 1.101) | 0.944 |
| Prostate | UKB + FinnGen | 1.010 (0.988, 1.032) | 0.380 | UKB + FinnGen | 1.003 (0.983, 1.018) | 0.972 | UKB + FinnGen | 1.020 (0.997, 1.045) | 0.090 |
| Breast | UKB + BCAC | 1.059 (1.033, 1.086) | < 0.0001 | UKB + BCAC | 1.029 (1.002, 1.055) | 0.032 | UKB + FinnGen + BCAC | 1.016 (0.981, 1.053) | 0.372 |
| Skin cancer | |||||||||
| Malignant melanoma | UKB + FinnGen | 1.030 (0.994, 1.068) | 0.105 | UKB + FinnGen | 1.021 (0.990, 1.053) | 0.183 | UKB + FinnGen | 1.042 (0.979, 1.110) | 0.196 |
| Malignant nonmelanoma | None | / | / | None | / | / | None | / | / |
| Other | |||||||||
| Eye and annexa | UKB + FinnGen | 1.098 (0.967, 1.246) | 0.150 | UKB + FinnGen | 1.073 (0.961, 1.198) | 0.212 | UKB + FinnGen | 1.018 (0.886, 1.170) | 0.804 |
| Kidney | UKB + FinnGen + IARC | 0.995 (0.962, 1.030) | 0.791 | UKB + FinnGen + IARC | 1.022 (0.970, 1.077) | 0.417 | UKB + FinnGen + IARC | 0.983 (0.946, 1.021) | 0.366 |
| Bladder | UKB + FinnGen | 0.993 (0.956, 1.031) | 0.703 | UKB + FinnGen | 1.004 (0.972, 1.037) | 0.799 | UKB + FinnGen | 0.986 (0.945, 1.028) | 0.502 |
| Bone | UKB + FinnGen | 1.050 (0.918, 1.201) | 0.475 | UKB + FinnGen | 1.005 (0.899, 1.124) | 0.930 | UKB + FinnGen | 0.958 (0.826, 1.111) | 0.572 |
| Brain | UKB + FinnGen | 1.043 (0.935, 1.163) | 0.448 | UKB + FinnGen | 1.064 (0.992, 1.127) | 0.067 | UKB + FinnGen | 1.039 (0.969, 1.114) | 0.285 |
| Thyroid | UKB + FinnGen + Kohler A et.al | 1.018 (0.960, 1.081) | 0.548 | UKB + FinnGen + Kohler A et.al | 1.023 (0.975, 1.074) | 0.358 | UKB + FinnGen + Kohler A et.al | 0.990 (0.927, 1.057) | 0.768 |
OR Odds ratio, CI Confidence interval, ILCCO The International Lung Cancer Consortium, BCAC Breast Cancer Association Consortium, OCAC The Ovarian Cancer Association Consortium, IARC International Agency for Research on Cancer